Format

Send to

Choose Destination
J Atten Disord. 2019 Jan;23(2):111-120. doi: 10.1177/1087054717696773. Epub 2017 Apr 3.

Safety of Treatments for ADHD in Adults: Pairwise and Network Meta-Analyses.

Author information

1
1 Universidade Estadual do Oeste do ParanĂ¡, Cascavel, Brazil.
2
2 Universidade Federal do ParanĂ¡, Curitiba, Brazil.
3
3 Universidade de Lisboa, Lisboa, Portugal.

Abstract

OBJECTIVE:

The aim of the study was to analyze evidence comparing the profile of drugs used to treat ADHD in adult patients.

METHOD:

Systematic searches were conducted in electronic databases. Randomized, double-blind, parallel controlled trials that evaluated the safety of drugs in ADHD were included. The statistical analyses were conducted by pairwise meta-analyses and mixed treatment comparison (MTC).

RESULTS:

Ten ( n = 3006) trials were included in the analyses. We observed statistical differences for the following outcomes: decreased appetite between atomoxetine and placebo (odds ratio [OR] = 0.15, 95% credibility interval [CrI] = [0.05, 0.38]) and extended-release mixed amphetamine salts and placebo (OR = 0.06, 95% CrI = [0.00, 0.51]); insomnia between atomoxetine and placebo (OR = 0.48, 95% CrI = [0.27, 0.88]) and extended-release mixed amphetamine salts and placebo (OR = 0.23, 95% CrI = [0.06, 0.76]); sleepiness between atomoxetine and methylphenidate OROS (OR = 0.24, 95% CrI = [0.06, 0.97]); and decreased libido between atomoxetine and placebo (OR = 0.28, 95% CrI = [0.08, 0.90]).

CONCLUSION:

It was possible to generate evidence about the safety profile of different ADHD drugs.

KEYWORDS:

ADHD; adult ADHD treatment; decision making; review

PMID:
28366111
DOI:
10.1177/1087054717696773

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center